Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Plans to Provide Indemnity to Coronavirus Vaccine Suppliers
August 21, 2020
-
BUSINESS Boehringer’s Ofev Already Hits Japan Peak Sales Outlook, Momentum Likely to Continue with New Indications
August 20, 2020
-
REGULATORY Entresto, Enerzair, 2 More HIF-PH Inhibitors OK'ed for Listing on August 26
August 19, 2020
-
BUSINESS Novo to Skip August Listing for 1st Oral GLP Agent Rybelsus
August 18, 2020
-
BUSINESS Pfizer Japan Takes Generic Contenders to Court over Lyrica Patent
August 18, 2020
-
ACADEMIA Generic APIs at Crossroads - 4: Professor Calls for Monitoring Drugs Liable to Be in Short Supply, Drawing Up Lists of Substitutes
August 17, 2020
-
ACADEMIA Generic APIs at Crossroads - 3: Gx Society Sets Up Committee for Discussions with Healthcare Providers and API Manufacturers
August 14, 2020
-
ORGANIZATION Generic APIs at Crossroads - 2: Traders’ Group Urges Simpler Regulatory Procedures to Facilitate API Substitution
August 13, 2020
-
BUSINESS Biosimilars Showing Accelerated Uptick in Japan, Doctor Fee Incentive as Tailwind
August 12, 2020
-
ORGANIZATION JMA’s New Pharma Affairs Exec Wants More Stringent Rules on Sakigake, Conditional Approval
August 11, 2020
-
REGULATORY AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
-
BUSINESS Axcelead Chief Says Small-Molecule Drug Targets More than Doubled in Last Few Years; IPO Eyed in 4-5 Years
August 7, 2020
-
BUSINESS GSK, KM Biologics in Adjuvant Tech Transfer Talks for COVID-19 Vaccines
August 7, 2020
-
BUSINESS MSD Japan Chief Wants Talks with Govt, Re-Pricing Rules Revisited to Help Innovation Thrive
August 6, 2020
-
BUSINESS Celltrion Poised to Roll Out 20 Biosimilars in Japan over Next 10 Years
August 5, 2020
-
BUSINESS Povidone-Iodine Gargle Meds Fly Off Pharmacy Shelves after Osaka COVID-19 Data
August 5, 2020
-
BUSINESS Daiichi Sankyo to Curb Shipments for Herceptin Biosimilar on Surging Demand
August 4, 2020
-
BUSINESS BMS Japan to Integrate Celgene Next Year, HQ Relocation Planned in H1 2022: Chief
August 3, 2020
-
REGULATORY Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
-
BUSINESS Teva Takeda Narrowing Focus on Unique Generics, Eyes Innovative Meds: CEO
July 31, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…